IL21 and Miyoshi myopathy: In Phase I and IIa clinical trials, IL-21 was well tolerated and triggered moderate antitumor activity in some renal cell carcinoma (RCC) and metastatic melanoma (MM) patients [10], [11], [12], [13], [14].